Therapeutic potential of urine-derived stem cells in renal regeneration following acute kidney injury: A comparative analysis with mesenchymal stem cells

Figure 7 Detection of urine-derived stem cells or bone marrow mesenchymal stem cells within the kidneys of acute kidney injury mice by human leucocyte antigen immunostaining. A-C: Representative micrographs showing human leucocyte antigen (HLA)-positive cells in kidney tissue from acute kidney injury (AKI) mice injected with urine-derived stem cells at days 5, 9 and 18; D-F: Representative micrographs showing HLA-positive cells in kidney tissue from AKI mice injected with bone marrow mesenchymal stem cells on days 5, 9 and 18; G: Graphs illustrating the quantification of HLA-positive cells. Student’s t test was performed between urine-derived stem cell-treated and bone marrow mesenchymal stem cell-treated AKI mice at each time point. ^aP < 0.01. USC: Urine-derived stem cell; BMSC: Bone marrow mesenchymal stem cell; HLA: Human leucocyte antigen.